FDA Fast Track Accelerates Gamgertamig for Refractory AIHA FDA Fast Track designation highlights gamgertamig’s potential to address unmet needs in cold and warm AIHA, as well as ITP.

The @fda.gov has granted #FastTrack designation to #Gamgertamig (#OM336) for the treatment of cold and warm autoimmune hemolytic anemia (#AIHA) and immune thrombocytopenia (#ITP),

Read here: https://bit.ly/4bz3UeT

#RareDisease #MedSky

Ouro Medicines Expands Clinical Development of OM336 for Sjögren's Disease and IIM Ouro Medicines has officially announced the expansion of its clinical development for OM336, targeting Sjögren's disease and idiopathic inflammatory myopathy, promising new hope for patients.

Ouro Medicines Expands Clinical Development of OM336 for Sjögren's Disease and IIM #United_States #South_San_Francisco #Ouro_Medicines #Sjögren's_Disease #OM336

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status Ouro Medicines has initiated a clinical study of OM336 for autoimmune cytopenias and received the FDA’s Orphan Drug Designation for AIHA.

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status #USA #San_Francisco #Ouro_Medicines #Autoimmune_Diseases #OM336

Ouro Medicines Takes a Bold Step in Autoimmune Treatment with New Clinical Trial for OM336 Ouro Medicines announces plans for a clinical trial of OM336, aimed at tackling autoimmune cytopenias. Exciting case studies emerge in NEJM, advocating the potential of this therapy.

Ouro Medicines Takes a Bold Step in Autoimmune Treatment with New Clinical Trial for OM336 #United_States #San_Francisco #Ouro_Medicines #OM336 #Autoimmune_Cytopenias